3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
Follow LY3300054: new trials by email Literature Review of LY3300054 trials Research Report on LY3300054
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors LY3300054, Prexasertib - Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 17 | 2018-05-16 | 2021-04-15 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors LY3381916, LY3300054 - Solid Tumor, Non Small Cell Lung Cancer | Phase 1 | Terminated | Eli Lilly and Company | 60 | 2017-11-17 | 2020-06-09 |
| A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors LY3321367, LY3300054 - Solid Tumor | Phase 1 | Completed | Eli Lilly and Company | 209 | 2017-04-12 | 2023-10-17 |
| A Study of LY3200882 in Participants With Solid Tumors LY3200882, LY3300054, Gemcitabine - Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 223 | 2016-11-21 | 2026-04-03 |
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors LY3300054, Ramucirumab, Abemaciclib - Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors | Phase 1 | Completed | Eli Lilly and Company | 164 | 2016-06-29 | 2024-09-27 |
Breast Neoplasms (1) · Camurati-Engelmann Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Eli Lilly and Company (4) · Dana-Farber Cancer Institute (1)
United States (5) · Spain (4) · France (3) · Belgium (2) · Canada (2) · Italy (2) · Japan (2) · South Korea (2) · Australia (1) · Denmark (1) · Germany (1) · Taiwan (1)
PMID 33229456, PMID 33514524, PMID 33745032, PMID 34465599, PMID 34548321
2016 (3), 2017 (1)